首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   173045篇
  免费   15596篇
  国内免费   8152篇
耳鼻咽喉   2304篇
儿科学   3845篇
妇产科学   2022篇
基础医学   31638篇
口腔科学   5504篇
临床医学   13376篇
内科学   23401篇
皮肤病学   4478篇
神经病学   9654篇
特种医学   3844篇
外国民族医学   126篇
外科学   15614篇
综合类   26525篇
现状与发展   48篇
预防医学   4674篇
眼科学   3632篇
药学   13110篇
  31篇
中国医学   5083篇
肿瘤学   27884篇
  2024年   359篇
  2023年   2489篇
  2022年   4439篇
  2021年   6224篇
  2020年   5528篇
  2019年   5346篇
  2018年   5561篇
  2017年   5840篇
  2016年   6132篇
  2015年   7051篇
  2014年   10196篇
  2013年   11312篇
  2012年   9778篇
  2011年   11026篇
  2010年   9187篇
  2009年   8792篇
  2008年   9260篇
  2007年   9473篇
  2006年   8594篇
  2005年   7874篇
  2004年   6958篇
  2003年   5963篇
  2002年   4903篇
  2001年   4180篇
  2000年   3447篇
  1999年   3099篇
  1998年   2932篇
  1997年   2675篇
  1996年   2402篇
  1995年   2090篇
  1994年   1848篇
  1993年   1538篇
  1992年   1243篇
  1991年   1179篇
  1990年   910篇
  1989年   850篇
  1988年   797篇
  1987年   637篇
  1986年   589篇
  1985年   784篇
  1984年   696篇
  1983年   486篇
  1982年   514篇
  1981年   410篇
  1980年   343篇
  1979年   257篇
  1978年   185篇
  1977年   139篇
  1976年   106篇
  1975年   39篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
目的探讨Survivin在食管癌组织中的表达及其与bcl-2蛋白表达的相关性。方法应用免疫组织化学SP法,检测Survivin、bcl-2蛋白在68例食管癌组织和20例正常食管组织中的表达。结果Survivin蛋白在正常食管组织中低表达或不表达,68例食管癌组织中,49例表达阳性,占72.1%。Survivin蛋白表达与分化程度、淋巴结转移密切相关(P<0.05)。食管癌组织bcl-2蛋白表达阳性、阴性组中,Survivin蛋白阳性表达率分别为94.7%(36/38)和43.3%(13/30),两者比较,差异有统计学意义(P<0.05)。Survivin蛋白表达与bcl-2蛋白表达密切相关。结论Survivin在食管癌组织中表达上调,通过抑制细胞凋亡,在食管癌的发生中起到重要作用;凋亡相关基因bcl-2的上调与Survivin的表达可能在食管癌变中起协同作用。  相似文献   
63.
PTEN及Bcl-2蛋白在膀胱移行细胞癌中的表达及其意义   总被引:1,自引:0,他引:1  
乔宝民  孙光  畅继武  韩瑞发  王文成  马腾骧 《天津医药》2006,34(12):844-845,I0004
目的:探讨PTEN及Bcl-2蛋白在膀胱移行细胞癌的表达规律及其临床意义。方法:应用免疫组织化学链亲和素-生物素-霉复合物(SP)方法检测43例膀胱移行细胞癌和7例正常黏膜组织中PTEN及Bcl-2蛋白的表达.分析二者的表达与膀胱癌病理参数的关系。结果:(1)G1、G2、G3肿瘤PTEN表达阳性率分别为85.7%、80.4%、73.3%,浸润性肿瘤和表浅性肿瘤表达阳性率分别为70.4%和93.8%,说明PTEN表达阳性率与肿瘤病理分级、临床分期有关。(2)G。、G2、G3肿瘤Bcl-2表达阳性率分别为14.2%、57.14%、66.67%,浸润性肿瘤和表浅性肿瘤表达阳性率分别为59.3%和43.8%,说明Bcl-2表达阳性率与肿瘤病理分级、临床分期有关。(3)随着肿瘤恶性程度的增高和临床分期进展,PTEN蛋白阳性率呈下降,Bcl-2表达呈增高趋势,二者表达呈负相关关系。结论:PTEN的抑癌作用可能与Bcl-2有关.二者的异常表达在膀胱移行细胞癌的发生、发展过程中起重要作用。二者同时检测有助于判断预后。  相似文献   
64.
65.
The antiproliferative, cytotoxic and apoptogenic activities of Bufo melanostictus (Indian common toad) skin extract (TSE) on U937 and K562 leukemic cell line has been investigated. TSE significantly (P<0.001) reduced the time-dependent cell proliferation and decreased MTT values in U937 and K562 cells. TSE (IC50 doses) suppressed the proliferating cell nuclear antigen expression in both the cells. It was demonstrated that, TSE (IC50 doses) primarily arrested the U937 and K562 cells at G1 phase of the cell cycle. Confocal microscopy showed the altered fragmented nuclei and apoptotic bodies formation in TSE (IC50 doses) treated U937 and K562 cells. Membrane blebbing, cell surface shrinkage and perforation were observed through scanning electron microscope. TSE-induced DNA fragmentation in U937 and K562 cells was reflected in single-cell gel electrophoresis. TSE significantly (P<0.001) increase the length-width ratio of DNA mass as compared to control in comet assay. The flow cytometric analysis of annexin-V binding to the cancer cells further supported the apoptotogenic activity of TSE. The effect of TSE on normal human peripheral blood mononuclear cells viability and cytotoxicity was studied in culture and found to be less cytotoxic than on the U937 and K562 cells. The findings from the present study suggested that TSE might possess potent antineoplastic agent having antiproliferative, cytotoxic and apoptogenic activity against U937 and K562 myeloid leukemic cells.  相似文献   
66.
Abstract  Gastrointestinal stromal tumor (GIST) is a recently described mesenchymal tumor that can develop in any portion of the gastrointestinal tract. The occurrence of a GIST in the urinary tract is rare, but GIST can present as tumor of the urinary tract or invade the urinary tract. This is the first reported case of GIST in the ileal neobladder, which presented as a submucosal tumor. The patient underwent an open exploration and partial resection of the neobladder pouch.  相似文献   
67.
目的 探讨负载膀胱癌冻融抗原对树突状细胞(DCs)分泌IL-12的影响。方法 反复冻融法获得膀胱癌细胞株BIU-87细胞抗原;联合应用重组人的GM-CSF、IL-4和TNF-α体外诱导健康志愿者DCs并负载膀胱癌肿瘤抗原;用ELISA法检测第3、6和9天培养细胞的上清液,评价DCs分泌IL-12 p70的能力。结果 联合应用重组人的GM-CSF、IL-4和TNF-α可在体外诱导出DCs;经ELISA方法检测,不同时期的DCs分泌IL-12的量不同,而且负载抗原DCs较未负载抗原DCs有更强的分泌能力(P〈0.05)。结论 IL-12 p70的分泌量受DCs的成熟状态及某些刺激信号的影响,膀胱癌冻融抗原是其刺激信号之一。  相似文献   
68.
AIM: The clinical significance of the urinary white blood cell (U-WBC) count and serum C-reactive protein (CRP) level was evaluated in an effort to improve the efficiency of prostate biopsies. METHODS: We enrolled 228 consecutive patients with serum prostate-specific antigen (PSA) ranging from 3.0 to 20.0 ng/mL, normal digital rectal examination findings, and who underwent prostate biopsies between January 2001 and August 2004. Of these, 157 patients had histologically confirmed benign prostatic disease and the remaining 71 patients had prostate cancer. Patients with a pretreatment U-WBC count < or =3 or >3/high power field were defined as non-pyuria and pyuria, respectively. The patients were also separated into two groups based on the serum CRP level prior to biopsy. Several clinical factors were compared among these subgroups. RESULTS: Inflammation was histologically detected at rates of 58.1% and 34.1% in the pyuria and non-pyuria groups, respectively (P = 0.0014). The rates of cancer detection were significantly lower in the pyuria, than in the non-pyuria group (P = 0.0384). The cancer detection rates did not significantly differ according to serum CRP levels prior to biopsy. CONCLUSION: The U-WBC count appears to be a reliable indicator of minute prostatic inflammation. The serum PSA level was elevated in patients with asymptomatic prostatitis. Counting U-WBC is a simple, convenient and non-invasive method that should be valuable part of routine urological examinations.  相似文献   
69.
BACKGROUND: 1Alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2) Vitamin D(3)] induces growth inhibition in squamous cell carcinoma (SCC) cell lines of the head and neck by arresting the cells in the G0/G1 phase of the cell cycle, probably due to an enhanced expression of p21, which could be demonstrated in other cell lines (JPPA, SCC9) before. In SCC25, a SCC cell line isolated from tongue, growth inhibition but no overexpression of p21 was detected. The retinoblastoma gene, as a direct target of G1 cyclin-CDK complexes, showed an obvious shift from the hyperphosphorylated to the hypophosphorylated form under 1,25(OH)(2)Vitamin D(3), which indicates that the growth inhibition takes place in the G0/G1 phase. To explore the possible pathway of growth inhibition in SCC25 we investigated other cell cycle inhibitors (p18, p19, p27). METHODS: Synchronized cells were treated with 1,25(OH)(2)Vitamin D(3) over 96 h. The cell cycle status and expression of cell cycle-regulating proteins was determined by fluorescence-activated cell sorting (FACS) and Western blotting. An overexpression of p18 in 1,25(OH)(2)Vitamin D(3) vs. ethanol-treated cells was determined until 30 h in SCC25. No influence was detectable on the expression of p27 and p19. CONCLUSION: One mechanism by which 1,25(OH)(2)Vitamin D(3) controls cell growth might be the upregulation of p21. As p21 was unsusceptible to 1,25(OH)(2)Vitamin D(3) in SCC25, other inhibiting proteins were necessary to be tested. The proven upregulation of p18 seems to be the responsible step for growth inhibition of 1,25(OH)(2)Vitamin D(3) in SCC25.  相似文献   
70.
Intrastriatal transplantation of striatal neuroblasts from human fetuses is a promising approach for treatment of Huntington's disease, on the basis of many experimental animal studies and, most recently, pilot clinical trials. Technically, several issues remain to be resolved (e.g., the precise site of dissection of the fetal tissue; the number and location of the fetal striatal implants; or the use of immunosuppressive therapy), and await larger-scale trials and purposely designed protocols. Further clinical data must also be obtained, and preliminary promising results must be replicated in a patient group large enough to provide conclusive results. It is important to establish (1) the amount of clinical benefit provided to the patient by the grafted cells; (2) the anticipated duration of clinical benefits; and (3) the secondary rate of decline after the benefit of the graft has been overbalanced. Evaluation of these parameters will require very long-term follow-up of the patients involved, over several years after grafting, before the technique can eventually be proposed widely to patients.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号